View Item 

Show simple item record

Phase II Trial of Suramin in Patients with Metastatic Renal Cell Carcinoma
dc.contributor.authorDreicer, Roberten_US
dc.contributor.authorSmith, David C.en_US
dc.contributor.authorWilliams, Richard D.en_US
dc.contributor.authorSee, William A.en_US
dc.date.accessioned2006-09-11T15:46:47Z
dc.date.available2006-09-11T15:46:47Z
dc.date.issued1999-05en_US
dc.identifier.citationDreicer, Robert; Smith, David C.; Williams, Richard D.; See, William A.; (1999). "Phase II Trial of Suramin in Patients with Metastatic Renal Cell Carcinoma." Investigational New Drugs 17(2): 183-186. <http://hdl.handle.net/2027.42/45194>en_US
dc.identifier.issn0167-6997en_US
dc.identifier.issn1573-0646en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/45194
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=10638490&dopt=citationen_US
dc.description.abstractThis study was conducted to assess the efficacy and toxicity of suramin administered using a fixed dose schedule in patients with advanced renal cell carcinoma. Fourteen eligible patients with advanced renal cell carcinoma were enrolled and treated on a fixed dose schedule of suramin administered over 12 weeks. Suramin was administered by intravenous infusions over 1 hour. None of the 13 evaluable patients demonstrated an objective response. Only 3 patients completed the 12-week therapy course, with the majority developing progressive disease on therapy. The fixed dosage schedule was well tolerated with minimal to moderate toxicity. Suramin in this fixed dose schedule is well tolerated but has no activity in advanced renal cell carcinoma.en_US
dc.format.extent44113 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers; Springer Science+Business Mediaen_US
dc.subject.otherMedicine & Public Healthen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.subject.otherOncologyen_US
dc.subject.otherCarcinomaen_US
dc.subject.otherRenal Cellen_US
dc.subject.otherNeoplasm Metastasisen_US
dc.subject.otherSuraminen_US
dc.titlePhase II Trial of Suramin in Patients with Metastatic Renal Cell Carcinomaen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelChemical Engineeringen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbsecondlevelRadiologyen_US
dc.subject.hlbtoplevelEngineeringen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Medicine, The University of Michigan, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherDepartment of Internal Medicine, The University of Iowa, Iowa City, IA, USA; he University of Iowa Cancer Center, Iowa City, IA, USA; Department of Urology, The University of Iowa, Iowa City, IA, USAen_US
dc.contributor.affiliationotherhe University of Iowa Cancer Center, Iowa City, IA, USA; Department of Urology, The University of Iowa, Iowa City, IA, USAen_US
dc.contributor.affiliationotherhe University of Iowa Cancer Center, Iowa City, IA, USA; Department of Urology, The University of Iowa, Iowa City, IA, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid10638490en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/45194/1/10637_2004_Article_242246.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1023/A:1006331518952en_US
dc.identifier.sourceInvestigational New Drugsen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
10637_2004_Article_242246.pdf
Size:
43.07KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.